Table 1.

Summary of findings of underuse, overuse, and misuse of G-CSF

Reference	Overuse, underuse, or misuse	Major finding
Freifield et al. [19]	Overuse, underuse	Nearly a third of physicians reported using G-CSF prophylactically in patients at low risk for FN (<20%), and 48% indicated that they use G-CSF as an adjunct to antibiotics to treat FN
Wright et al. [8]	Overuse, underuse	62.1% of low-risk patients and 65.9% of high-risk patients received G-CSF to treat FN
Ramsey et al. [5]	Overuse, underuse	50% of high-risk patients received G-CSF; 21% of cancer patients at little or no risk received a G-CSF
Barron et al. [30]	Underuse	G-CSF prophylaxis was frequently used less often than antibiotic prophylaxis
Potosky et al. [7]	Underuse, misuse	17% of high-risk, 18% of intermediate-risk, and 10% of low-risk (<10%) patients received prophylactic G-CSF. In most cases, the use of G-CSF was therapeutic or reactive to preexisting FN
Waters et al. [29]	Overuse	46% of prophylactic G-pegylated CSF dosages were classified as not needed in patients undergoing low- or intermediate-risk cancer regimen